噬血细胞性淋巴组织细胞增多症 (HLH) 是一种罕见的危及生命的疾病，其特征是免疫系统大规模过度激活。由于临床结果不具有特异性，因此开发有助于快速诊断的检测方法对于患者护理至关重要。本研究的目的是评估 HLH 生物标志物的微流控酶联免疫吸附测定 (ELISA) 的性能，并调查内包该测试对三级癌症医院的工作流程、成本和周转时间的影响。对 C-X-C 基序趋化因子配体 9 (CXCL9) 和可溶性白介素 2 受体 ɑ (sIL2R) 的订单量进行了评估，并使用微流体 ELISA 测量血清样品中的这些分析物。将该测定的分析物值、周转时间和成本与参考实验室测试进行了比较。在过去 5 年中，每年的测试订单请求从 187 份增加到 1030 份。在半自动 ELISA 上采购这些分析物可以将获得结果的时间缩短约 2 天，并在我们的实验室每年节省约 140,000 美元的成本。使用半自动 ELISA 检测 sIL2R 和 CXCL9 可以帮助医生做出诊断并监测患有以下疾病的患者的治疗情况： HLH，同时减少临床实验室内的周转时间和成本。© 作者 2024。由牛津大学出版社代表美国临床病理学会出版。版权所有。如需商业重复使用，请联系 reprints@oup.com 获取转载和转载的翻译权。所有其他权限都可以通过我们网站文章页面上的权限链接通过我们的 RightsLink 服务获得 - 如需了解更多信息，请联系journals.permissions@oup.com。

Hemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening condition characterized by a massive overactivation of the immune system. Because the clinical findings are nonspecific, the development of assays to facilitate rapid diagnosis is critical for patient care. The objectives of this study were to evaluate the performance of a microfluidic enzyme-linked immunosorbent assay (ELISA) for HLH biomarkers and investigate the impact of insourcing this testing on workflow, cost, and turnaround time in a tertiary-care cancer hospital.Trends in order volume were evaluated for C-X-C motif chemokine ligand 9 (CXCL9) and soluble interleukin 2 receptor ɑ (sIL2R), and a microfluidic ELISA was used to measure these analytes in serum samples. Analyte values, turnaround time, and costs were compared for this assay relative to reference laboratory testing.Test ordering has increased from 187 to 1030 requests annually over the past 5 years. Insourcing these analytes on a semiautomated ELISA can decrease time to result by approximately 2 days and generate a cost savings of roughly $140,000 annually within our laboratory.Using a semiautomated ELISA for sIL2R and CXCL9 may help physicians arrive at a diagnosis and monitor therapy for patients with HLH while decreasing turnaround time and costs within the clinical laboratory.© The Author(s) 2024. Published by Oxford University Press on behalf of American Society for Clinical Pathology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.